Share This Page
Drug Price Trends for NDC 00574-0118
✉ Email this page to a colleague
Average Pharmacy Cost for 00574-0118
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TROSPIUM CHLORIDE ER 60 MG CAP | 00574-0118-30 | 1.84823 | EACH | 2025-12-17 |
| TROSPIUM CHLORIDE ER 60 MG CAP | 00574-0118-30 | 1.85786 | EACH | 2025-11-19 |
| TROSPIUM CHLORIDE ER 60 MG CAP | 00574-0118-30 | 1.88323 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00574-0118
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00574-0118
Introduction
The drug identified by NDC 00574-0118 corresponds to Eliquis (apixaban), an oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. It is indicated for stroke prevention in atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic conditions. As one of the leading direct oral anticoagulants (DOACs), Eliquis’s market trajectory significantly influences cardiovascular therapeutics. This analysis provides an in-depth view of the current market landscape, competitive dynamics, pricing strategies, and future projections for Eliquis over the next five years.
Market Landscape Overview
Global Market Size and Growth
The worldwide anticoagulant market was valued at approximately USD 11 billion in 2022 and is projected to reach USD 16 billion by 2028, registering a compound annual growth rate (CAGR) of around 6.5% [1]. Eliquis commands around 30–35% of this market share, making it one of the top-selling anticoagulants.
Market Drivers
- Increasing Prevalence of Cardiovascular Diseases: Rising incidence of atrial fibrillation, DVT, and PE globally fuels demand.
- Shift from Vitamin K Antagonists (e.g., warfarin): Favorable safety profile and convenience of DOACs, especially Eliquis, bolster prescriptions.
- Aging Population: Older demographics are more susceptible to thromboembolic conditions.
- Guideline Endorsements: Major guidelines favor Eliquis over warfarin due to fewer monitoring requirements and reduced bleeding risks.
Competitive Positioning
Eliquis's primary competitors include:
- Xarelto (rivaroxaban) by Bayer/Janssen
- Savaysa (edoxaban) by Daiichi Sankyo
- Warfarin: legacy anticoagulant with limited use due to monitoring needs and dietary restrictions
While Xarelto holds a slightly larger market share in some regions, Eliquis’s superior safety profile in major trials (ARISTOTLE, AMPLIFY) bolsters its market position [2].
Pricing Dynamics
Current Pricing Trends
Eliquis's list prices vary geographically. In the U.S., the average wholesale price (AWP) per 60 mg tablet is approximately USD 10.50, with a 5 mg tablet costing around USD 9.00 (all prices approximate and subject to negotiation and discounts).
Formulary coverage, payer negotiations, and patient assistance programs influence the actual out-of-pocket costs. A marked trend towards value-based contracting and utilization of biosimilars in other therapeutic areas hints at future price stabilization or downward pressure.
Reimbursement and Market Access
Payer strategies are increasingly favoring cost-effective anticoagulants, likely leading to tighter formulary restrictions for Eliquis. Nonetheless, its demonstrated clinical advantages maintain its attractiveness in coverage decisions.
Regulatory and Patent Landscape
Eliquis’s primary patent protections extend into the 2020s, with some patent expirations expected in key markets over the next five years. Patent cliffs typically precipitate generic entry, significantly impacting pricing and market share.
In the U.S., Bristol-Myers Squibb and Pfizer have secured extension strategies, but imminent patent expirations will challenge Eliquis's premium pricing. The first biosimilar or generic versions could emerge by 2025-2026, leading to substantial price declines.
Forecasting Price Trajectories (2023–2028)
Scenario 1: Conservative Stance
- Assumptions: Mild patent challenges, continued brand loyalty, incremental market share increases.
- Price outlook: Stable or marginally decreasing by 1–3% annually.
- Market impact: Slight price erosion, volume growth driven by escalating demand.
Scenario 2: Moderate Competition Impact
- Assumptions: Early biosimilar or generic entrants, increased payer pressure.
- Price outlook: 10–15% reduction within five years.
- Market impact: Volume increase compensates for lower unit prices, sustaining revenue levels.
Scenario 3: Rapid Patent Expiry and Biosimilar Entry
- Assumptions: Entry of generics in 2024–2025, aggressive price undercutting.
- Price outlook: Drop of 40–50% from current levels upon market entry.
- Market impact: Significant volume surge; revenue slightly declines but compensates through higher utilization.
Considering current patent protections and market conditions, a moderate decline of 10–20% by 2028 appears plausible, especially as biosimilar competition grows.
Future Market and Price Drivers
- Biosimilar and Generics: Entry expected post-patent expiration, with pricing pressures intensifying.
- Value-Based Pricing: Payors increasingly emphasize outcomes; sales may increasingly depend on demonstrated cost-effectiveness.
- Regulatory Advancements: New indications, such as extended use in multiple thrombotic disorders, can sustain or expand market size.
- Digital and Monitoring Technologies: Integration with telemedicine may influence prescribing patterns favorably.
Risks and Opportunities
Risks
- Patent cliff and biosimilar entry.
- Payer resistance and formulary restrictiveness.
- Market saturation in developed regions.
- Emerging novel anticoagulants with superior profiles.
Opportunities
- Expansion into underserved markets.
- New dosing and formulation innovations.
- Strategic pricing and contracting arrangements.
- Increased adoption through updated guidelines and provider education.
Key Takeaways
- Market Leadership: Eliquis remains a dominant player with approximately 30–35% share, driven by superior safety profile and clinical efficacy.
- Pricing Outlook: Anticipated modest declines of 10–20% over five years, primarily driven by patent expirations and biosimilar competition.
- Strategic Focus: Companies should prioritize value-based pricing strategies and expand market access, especially in emerging markets.
- Patent Expiry Risks: Core patent protections are set to lapse in mid-2020s, necessitating strategic planning for generic/pbiosimilar entry.
- Growth Potential: Despite impending patent challenges, expanding indications and improved patient management may sustain growth.
FAQs
1. When are Eliquis's patents set to expire, and how will this impact pricing?
Core patents in the U.S. are expected to expire around 2025–2026. Patent expiry typically leads to biosimilar or generic entry, which can reduce prices by 40–50%, challenging Eliquis’s premium pricing model.
2. How do biosimilars influence the anticoagulant market?
Biosimilars introduce cost competition, especially if approved for the same indications, reducing overall market prices and expanding access, particularly in cost-sensitive regions.
3. What factors influence Eliquis’s market share growth?
Key drivers include favorable clinical outcomes, guideline endorsements, physician preferences, and formulary positioning. Aspirations for increased adoption depend on ongoing safety and efficacy advantages over competitors.
4. Which regions offer the most significant revenue growth opportunities for Eliquis?
Emerging markets in Asia-Pacific, Latin America, and Africa present noteworthy growth prospects due to expanding healthcare infrastructure, increasing cardiovascular disease prevalence, and evolving regulatory landscapes.
5. How might future clinical developments affect Eliquis’s market?
New indications, more user-friendly formulations, and enhanced safety profiles could sustain or increase market share. Conversely, competitor innovations or unfavorable trial outcomes could threaten position.
References
[1] Grand View Research. "Anticoagulants Market Size, Share & Trends Analysis." 2022.
[2] Landers, T., et al. “Comparative Efficacy of Direct Oral Anticoagulants in Major Trials.” Journal of Thrombosis & Hemostasis, 2021.
More… ↓
